Institutional interest in "govx stock forecast" appears steady, with hedge fund positions unchanged in the last 30 days, signaling cautious optimism in high-risk biotech plays. The first half of fiscal 2024 was marked by numerous business wins for the company. GeoVax Labs, Inc. (NASDAQ:GOVX) received the BARDA Project NextGen award to advance the development of its dual-antigen next-generation COVID-19 vaccine. The initial award amounts to $24.4 million but has the potential to increase as much as $45 million. CSX Stock Rally: Strong Options Flow, Analyst Price Targets Options market data reveals unusual call volume for "govx stock forecast", possibly signaling investor expectations of a short-term rally.
